Moreover, using rosiglitazone or ACSL4 Small interfering RNA (siRNA) can suppress ACSL4 expression, downregulate the Mfn2/IRE1α pathway, and reduce the levels of 5-hydroxy eicosatetraenoic acid, thereby significantly alleviating ferroptosis and NASH [195]. Here, ACSL4 is linked to metabolic dysfunction-associated steatohepatitis.